
    
      The trial will recruit 162 patients with unresectable HCC, and they will be randomized (1:1)
      into two groups (TACE+sorafenib group, TACE group). Patients in TACE+sorafenib group will
      receive TACE one day following oral sorafenib (initial dose: 400mg BID). Patients in the TACE
      group will receive TACE alone.
    
  